GUO Bin 1ZHANG Yuan 2DONG Jing 2XU Zhenhua 2SHI Zhen2
作者信息
- 1. Department of Tumor Radiotherapy,Jinshazhou Hospital of Guangzhou University of Traditional Chinese Medicine,Guangzhou 510168,China
- 折叠
摘要
Abstract
Objective:To explore the application effect of Camrelizumab combined with second-line therapy in triple negative breast cancer(TNBC).Method:A total of 102 TNBC patients admitted to Jinshazhou Hospital of Guangzhou University of Traditional Chinese Medicine from January 2023 to January 2025 were taken as the research objects and divided into two groups by random number table method,with 51 cases in each group.The control group was given second-line treatment(Apatinib+Capecitabine),and on this basis,the study group was given Camrelizumab treatment.With 21 days as one treatment cycle,both groups were treated for 4 cycles.The disease control rate and the incidence of toxic and side effects of the two groups were statistically analyzed.The levels of tumor markers[thymidine kinase 1(TK1),carcinoembryonic antigen(CEA),tissue polypeptide specific antigen(TPS),carbohydrate antigen 125(CA125)],immune function(CD4+,CD8+,CD4+/CD8+)and apoptotic factors[cyclooxygenase-2(COX-2),decoy receptor 3(DcR3)]of the two groups were compared before treatment and after 4 cycles of treatment.Result:After 4 cycles of treatment,the disease control rate of the study group was higher than that of the control group(P<0.05).Compared with before treatment,the levels of TPS,TK1,CEA and CA125 in both groups after 4 cycles of treatment were lower,and those in the study group were lower than those in the control group(P<0.05).Compared with before treatment,the levels of COX-2 and DcR3 in both groups after 4 cycles of treatment were lower,and those in the study group were lower than those in the control group(P<0.05).Compared with the control group,the CD4+and CD4+/CD8+levels in the study group after 4 cycles of treatment were higher,and the CD8+levels was lower(P<0.05).There were no statistically significant differences in the incidence of anemia,hypertension,neutropenia and leukopenia between the two groups(P>0.05).Conclusion:Camrelizumab combined with second-line treatment(Apatinib+Capecitabine)in TNBC patients can enhance the therapeutic effect,improve immune function,and will not increase toxic and side effects.关键词
三阴性乳腺癌/卡瑞利珠单抗/阿帕替尼/卡培他滨/免疫功能/凋亡抑制因子Key words
Triple negative breast cancer/Camrelizumab/Apatinib/Capecitabine/Immune function/Apoptotic inhibitory factor
